Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11835236 | 0.85 | AVPR1A (0.47) | AVPR1AOPRD1 | |
| SCHEMBL24988371 | 0.83 | AVPR1A (0.36) | AVPR1A | |
| SCHEMBL12164932 | 0.82 | SLC6A4 (0.39) | PARP1SLC6A4 | |
| SCHEMBL20290358 | 0.82 | SIGMAR1 (0.38) | OPRD1 | |
| SCHEMBL24988726 | 0.80 | SLC6A2 (0.35) | PARP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12164938 | 0.78 | MAPT (0.46) | KDM4E | |
| SCHEMBL24988737 | 0.78 | AVPR1A (0.34) | AVPR1AOPRD1 | |
| SCHEMBL16939880 | 0.78 | AVPR1A (0.36) | AVPR1A | |
| SCHEMBL21788649 | 0.77 | OPRD1 (0.45) | AVPR1AOPRD1 | |
| SCHEMBL8555154 | 0.76 | GRIN1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858904-B2 | Process for preparing large size isoxazoline particles | INTERVET INC. (JE) | 2024-01-02 | — | — | US | disclosed |
| EP-3668866-B1 | PESTICIDAL AND PARASITICIDAL PYRAZOLE-ISOXAZOLINE COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2023-01-18 | — | — | EP | disclosed |
| WO-2020225143-A1 | INJECTABLE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTERVET INTERNATIONAL B.V. (NL) | 2020-11-12 | — | — | WO | disclosed |
| WO-2019036407-A1 | PESTICIDAL AND PARASITICIDAL PYRAZOLE-ISOXAZOLINE COMPOUNDS | MERIAL, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-9371293-B2 | Isoxazoline compound composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150119432-A1 | ISOXAZOLINE COMPOUND COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-04-30 | — | — | US | disclosed |
| US-20140107127-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858904-B2 | Process for preparing large size isoxazoline particles | PDE8A, RPS4X, MRPS27 | AVPR1A 783/4885KDM4E 3208/4885ALDH1A1 1502/4885 |
| US-20150119432-A1 | ISOXAZOLINE COMPOUND COMPOSITION | CHRNA7, CYP3A7, CYP4X1 | AVPR1A 505/4885KDM4E 1605/4885ALDH1A1 1490/4885 |
| US-20140107127-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | ACHE, ABCC5, ABCC2 | AVPR1A 2959/4885KDM4E 2596/4885ALDH1A1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.